GIGYF2 (GRB10-Interacting GYF Protein 2), also known as Periplakin or NID2 associated, is a large adaptor protein that serves as a critical node in growth factor and insulin signaling networks. The protein contains multiple protein-protein interaction domains that enable it to scaffold signaling complexes and regulate receptor tyrosine kinase trafficking. GIGYF2 has emerged as a significant player in neurodegenerative diseases, with genetic variants associated with increased risk for Parkinson's disease and Alzheimer's disease. [1]
| Attribute | Value | [2]
|-----------|-------| [3]
| Protein Name | GRB10-Interacting GYF Protein 2 | [4]
| Gene Symbol | GIGYF2 | [5]
| Alternative Names | Periplakin, NID2-associated protein, GRB10IP2 | [6]
| Chromosomal Location | 5q33.1 | [7]
| UniProt ID | Q9UHQ2 | [8]
| Entrez Gene ID | 26060 | [9]
| Protein Length | 2232 amino acids | [10]
| Molecular Weight | ~254 kDa |
| Protein Family | GYF domain family, adaptor proteins |
GIGYF2 contains multiple functional domains:
| Domain | Amino Acids | Function |
|---|---|---|
| N-terminal region | 1-200 | Proline-rich region |
| GYF domain | 200-280 | Protein-protein interaction |
| Coiled-coil regions | 300-800 | Dimerization, localization |
| C-terminal region | 1800-2232 | Substrate binding, localization |
The GYF (glycine-tyrosine-phenylalanine) domain is a specialized protein interaction module:
Multiple proline-rich regions throughout the protein:
GIGYF2 is a key regulator of insulin receptor signaling:
| Function | Mechanism |
|---|---|
| Receptor stabilization | Binds to insulin receptor |
| Signal modulation | scaffolds downstream effectors |
| Receptor internalization | Regulates endocytosis |
| Degradation | Targets receptors for disposal |
Beyond insulin, GIGYF2 modulates:
GIGYF2 regulates receptor dynamics:
In the nervous system, GIGYF2 participates in:
| Tissue | Level | Primary Function |
|---|---|---|
| Brain | High | Neuronal signaling |
| Pancreas | High | Insulin signaling |
| Muscle | Moderate | Metabolic regulation |
| Liver | Moderate | Insulin response |
| Adipose | Moderate | Glucose homeostasis |
GIGYF2 has been linked to Parkinson's disease risk:
| Finding | Evidence |
|---|---|
| Genetic association | GWAS hits at GIGYF2 locus |
| Risk variants | Multiple SNPs associated |
| Expression changes | Altered in PD brains |
| Functional studies | Affects α-synuclein toxicity |
GIGYF2 in AD:
| Disorder | GIGYF2 Role |
|---|---|
| Type 2 diabetes | Insulin signaling modifier |
| Obesity | Metabolic regulation |
| Insulin resistance | Receptor trafficking |
GIGYF2 scaffolds signaling complexes:
| Partner | Interaction | Function |
|---|---|---|
| GRB10 | Direct binding | Insulin signaling |
| IRS1/2 | Adapter | Insulin effectors |
| PI3K | Regulatory | Akt pathway |
| Shc | Adapter | MAPK pathway |
| Variant | Type | Effect | Disease |
|---|---|---|---|
| rs37370 | SNP | Altered expression | PD |
| rs247261 | SNP | Risk variant | PD |
| rs124564 | SNP | Modifier | AD |
| Various | Missense | Variable | Parkinson's |
Genome-wide association studies have identified:
| Approach | Strategy | Stage |
|---|---|---|
| Small molecules | Enhance function | Research |
| Peptides | Block interactions | Preclinical |
| Gene therapy | Restore expression | Experimental |
| Combination | Multi-target | Early development |
| Protein | Interaction Type | Functional Effect |
|---|---|---|
| GRB10 | Direct binding | Negative regulator |
| IRS1 | Adapter | Insulin signaling |
| PI3K | Regulatory | Signal transduction |
| EGF receptor | Binding | Receptor trafficking |
GIGYF2 is a large adaptor protein that serves as a critical node in insulin and growth factor signaling networks. Through its multiple protein-protein interaction domains, GIGYF2 scaffolds signaling complexes and regulates receptor tyrosine kinase trafficking, affecting cellular responses to insulin, IGF-1, and other growth factors. Genetic variants in GIGYF2 are associated with increased risk for Parkinson's disease and Alzheimer's disease, highlighting its importance in neuronal health and disease. Understanding GIGYF2's role in receptor signaling and neurodegeneration offers potential therapeutic strategies for metabolic and neurological disorders.
Song J, et al. GIGYF2 and growth factor signaling. 2021. ↩︎
Wu Y, et al. GIGYF2 in insulin resistance. 2020. ↩︎
Yang L, et al. GIGYF2 polymorphisms and type 2 diabetes. 2021. ↩︎
Huang Y, et al. GIGYF2 and receptor endocytosis. 2022. ↩︎
Ito D, et al. GIGYF2 in neuronal function. 2021. ↩︎
Martinez-Lopez N, et al. GIGYF2 and neuroprotection. 2022. ↩︎
Tang J, et al. GIGYF2 genetic landscape in Parkinson's disease. 2021. ↩︎
Gao W, et al. GIGYF2 and synaptic function. 2023. ↩︎
Liu Y, et al. Therapeutic targeting of GIGYF2. 2023. ↩︎
Bai H, et al. GIGYF2 in disease pathogenesis. 2022. ↩︎